Argentina CFS Legalization Chain: Issuance, Apostille and Certified Translation
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Certificate of Free Sale (Certificado de Libre Venta, CFS) is a mandatory document for Argentine registration, and its legalization chain consists of 3 steps, none of which can be skipped: ① issuance by the competent authority of the country of manufacture and/or sale → ② an apostille (Apostille) or consular legalization → ③ a certified Spanish translation attached.
Validity rules: where no validity period is stated, the CFS is valid for 2 years from the date of issue (Part III, Article 6 of GMC 25/21); under the notification pathway of Disposición 236/2026, the CFS must be no more than 24 months old (Decreto 892/2025). The three most frequent grounds for rejection are a missing legalization, a missing translation, and an expired certificate. Each of the three is entirely avoidable with early planning, which is why the CFS chain deserves to be scheduled as a project of its own rather than an afterthought.
Operationally, the CFS deserves to be treated as a small supply chain of its own. The issuing authority works on its own queue, the apostille or consular step depends on that queue, and the sworn translation depends on receiving the legalized original. Because each step consumes the output of the previous one, the total lead time is the sum of three queues, not the longest of them. Mapping the three steps with realistic durations at the start of the project, and re-checking the mapping whenever the issuing authority or the destination pathway changes, converts an unpredictable source of delay into a plannable one.
2. Legal basis
| Regulatory instrument | Number | Publication date | Relevant provisions |
|---|---|---|---|
| MERCOSUR technical regulation for medical device registration | GMC/RES 25/21 | October 13, 2021 | Part III, Article 6 (CFS requirement and 2-year validity) |
| Framework for recognition of international regulatory equivalence | Decreto 892/2025 | 2025 | Annex I (list of reference countries) |
| Notification scheme for low and medium-risk products | Disposición ANMAT 236/2026 | Published February 6, 2026, effective 30 days after publication | Provision capping the CFS at 24 months |
| Domestic implementing instrument | Disposición ANMAT 64/2025 | Published in the Official Gazette on January 13, 2025 | Provisions on document requirements |
Read together, the four instruments define both the form and the lifespan of the CFS. GMC 25/21 and its domestic transposition fix the requirement itself and the default 2-year validity, Decreto 892/2025 defines which foreign CFS documents benefit from the reference-country framework, and Disposición 236/2026 sets the stricter 24-month cap for files that enter through the notification route.
3. Expert insights
Insight 1: the CFS is a chain of certificates, not a single sheet of paper. The three steps involve three different parties: the competent authority (issuance), the ministry of foreign affairs or an authorized body (apostille or consular legalization), and an Argentine sworn translator (translation). A gap at any step sends the file straight back at formal screening. The classic corporate mistake is to equate having obtained the CFS with having completed the chain, and to discover the missing apostille or translation only when ANMAT rejects the file.
Insight 2: the CFS route for companies from the Chinese mainland has a clear but limited position. Companies from the Chinese mainland usually base their CFS on the NMPA certificate for export and sale of medical device products, then obtain an apostille for it. That document serves as a basic document for the conventional registration pathway, but it is not a reference-country CFS under Annex I of Decreto 892/2025 and cannot trigger the local testing exemption of the 236/2026 pathway. This distinction directly determines which pathway is feasible for a given product.
Insight 3: validity management must distinguish two rules. The conventional registration pathway applies the default rule of 2 years where nothing is stated; the 236/2026 pathway applies the hard cap of no more than 24 months. The same CFS can produce a different compliance conclusion under each pathway, so the assessment must always be made against the pathway actually used for the submission, and re-checked whenever the pathway choice changes during project planning.
A useful discipline is to record, for every CFS in the portfolio, the issue date, the stated validity, the pathway for which it was procured and the date by which re-issuance must begin. With those four data points in one register, the compliance question for any upcoming submission becomes a lookup rather than an investigation, and the renewal trigger can be fired automatically instead of depending on someone remembering the expiry.
4. Practical recommendations
- Prioritize obtaining a reference-country CFS. If the product is already marketed in any of the European Union, the United States, the United Kingdom, Japan, Australia, Israel or an EFTA jurisdiction, apply for the CFS from the competent authority of that jurisdiction first; a single document can then satisfy both pathways at once.
- Run the three chain steps in parallel. Issuance, apostille or consular legalization and translation can be prepared by different parties at the same time, provided the translation is verified word for word against the original before filing.
- Put the CFS expiry date into the project calendar. Start re-issuance at least 3 months before expiry, with particular attention to Class III/IV projects, whose long review cycles make it easy for the certificate to lapse mid-review.
- Commission the translation from an Argentine sworn translator. Machine translation is not accepted, and terminology errors can trigger deficiency letters or even doubts about the product itself.
5. Verification checklist
- □ CFS issued by the competent authority of the country of manufacture or sale
- □ Apostille (Apostille) or consular legalization completed
- □ Certified Spanish translation attached
- □ Validity compliant with the rule of the applicable pathway (2-year default / 24-month cap)
- □ Feasibility of obtaining a reference-country CFS for the 236/2026 pathway assessed
- □ CFS expiry date entered in the project calendar with a renewal reminder
Regulatory information verified as of October 29, 2026.
In Argentina, GRZAN operates a wholly owned subsidiary that can serve as the registration holder and importer of record for foreign manufacturers, directly handling classification assessment, pathway selection, building the GMP and CFS documentation chain, Spanish-language localization of technical documentation and labeling, HELENA submissions and responses to deficiency letters, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and planning for the 5-year renewal. For support with registration dossiers and conformity documentation for the Argentine market, contact the GRZAN regulatory team at info@grzanglobal.com.
The GRZAN regulatory team consists of professionals with many years of hands-on experience in international registrations, tracks the activity of regulatory authorities across markets on an ongoing basis, and applies a writing standard of conclusions first, traceable sources and verifiable figures to everything it publishes. For a market access plan tailored to a specific product in Argentina or the wider MERCOSUR region, the GRZAN regulatory team welcomes your enquiry at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us